Загрузка...
The use of integrase inhibitors in treatment-experienced patients
Raltegravir, the first approved HIV-1 integrase inhibitor, is able to block the strand transfer step of the HIV proviral DNA integration process into the cellular host DNA. The selected dosage for the pivotal phase III studies (subsequently approved by the regulatory agencies) was 400 mg bid by oral...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3516826/ https://ncbi.nlm.nih.gov/pubmed/19959414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2047-783X-14-S3-30 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|